Pericarditis Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Pericarditis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2Phase 3

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

PericarditisRecurrent PericarditisPericarditis Acute
Kiniksa Pharmaceuticals International, plc165 enrolled46 locationsNCT07010159
Recruiting

CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome

PericarditisArthropathyCamptodactyly+1 more
Meyer Children's Hospital IRCCS15 enrolled10 locationsNCT07468461
Recruiting
Phase 3

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

Recurrent Pericarditis
Cardiol Therapeutics Inc.110 enrolled26 locationsNCT06708299
Recruiting
Phase 2

Transition to KPL-387 Monotherapy Dosing & Administration Study

PericarditisHeart DiseasesRecurrent Pericarditis
Kiniksa Pharmaceuticals International, plc80 enrolled6 locationsNCT07288216
Recruiting
Phase 2

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Recurrent Pericarditis
Zomagen Biosciences Ltd.50 enrolled16 locationsNCT06836232
Recruiting

COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry

PericarditisMyocarditis
Ottawa Heart Institute Research Corporation400 enrolled1 locationNCT05046002
Recruiting

Multimodal Analysis of Endomyocardial Biopsies

CardiomyopathiesHypertrophic Cardiomyopathy (HCM)Heart Transplantation+4 more
University Hospital, Essen216 enrolled1 locationNCT07359690
Recruiting
Phase 2

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Tuberculous PericarditisHIV Status
University of Cape Town60 enrolled2 locationsNCT04521803
Recruiting

Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels

Pericarditis
ASST Fatebenefratelli Sacco146 enrolled9 locationsNCT05925790
Recruiting
Not Applicable

Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis

Recurrent Pericarditis
Azienda Ospedaliero, Universitaria Ospedali Riuniti20 enrolled1 locationNCT06071156
Recruiting

The BioHeart Study: assessing patients with suspected cardiovascular disease for new disease markers and risk factors

PericarditisCardiomyopathyMyocarditis+1 more
Northern Sydney Local Health District - Royal North Shore Hospital5,000 enrolled7 locationsACTRN12618001322224